Case 2 – A case of secondary platinum-resistant ovarian cancer
DOI:
https://doi.org/10.19156/cbn.2017.0048Keywords:
advanced ovarian cancer, new biological drugs, quality of lifeAbstract
Patients with ovarian cancer relapsing during first-line treatment (refractory) or in the following few months (platinum-resistant) are a very heterogeneous group with various biological tumor behaviors. As this condition is linked to an unfavorable prognosis, the main objective of treatment is to palliate symptoms and preserve quality of life. While traditional chemotherapy may help to achieve this, new biological agents that have been introduced or are under development are expected to improve the quality of life and outcomes for patients with advanced ovarian cancer. This case report describes the clinical history of a 67-year-old woman with bilateral ovarian high grade serous papillary adenocarcinoma with lymph node and omentum metastasis.Downloads
Published
2017-08-17
How to Cite
1.
Di Napoli M, Lorusso D. Case 2 – A case of secondary platinum-resistant ovarian cancer: . CBN [Internet]. 2017 Aug. 17 [cited 2024 Nov. 23];5(2):46-50. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/184
Issue
Section
Meet the expert
License
Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.